Close menu




October 7th, 2025 | 07:35 CEST

AMD, NetraMark, Adobe – AI latecomers with significant catch-up potential

  • AI
  • Biotechnology
  • Biotech
  • Software
  • Technology
Photo credits: pixabay.com

The market is currently hotly debating when the AI bubble will finally burst. Investors are becoming increasingly nervous, as the valuations of many companies, such as Palantir and Nvidia, are at levels seen just before the dot-com bubble in the early 2000s. However, not all companies related to artificial intelligence are overvalued. Especially in niche segments, there are still hidden gems to be found that have the potential to multiply in value.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: ADVANCED MIC.DEV. DL-_01 | US0079031078 , NETRAMARK HOLDINGS INC | CA64119M1059 , ADOBE INC. | US00724F1012

Table of contents:


    AMD – Sensational news and share price explosion

    AMD shares exploded by a whopping 25% in pre-market trading after the announcement of a new billion-dollar deal in the semiconductor industry. According to the announcement, US chip manufacturer AMD secured a mega order from AI pioneer OpenAI. Starting in the second half of 2026, AMD will supply hundreds of thousands of high-performance GPUs to OpenAI. The chips are expected to provide a total output of six gigawatts and form the backbone of new data centers over several years. The first step will be a 1 GW facility based on the upcoming MI450 chip series, with which OpenAI aims to generate revenue starting in 2026.

    AMD CFO Jean Hu speaks of a "strategic milestone" that is expected to significantly increase non-GAAP earnings per share and strengthen the Company's position in the AI market in the long term. CEO Lisa Su is also euphoric: "This partnership is a true win-win situation and takes the global AI ecosystem to a new level."

    Another interesting fact is that OpenAI will have the option to acquire up to a 10% stake in AMD. Specifically, the ChatGPT developer can acquire up to 160 million AMD shares for only USD 0.01 each as part of the deal, provided that agreed milestones are reached. The first step will take place after delivery of the MI450 chips, with further tranches depending on ambitious price targets of up to USD 600 per share.

    "This partnership is an important step toward building the computing capacity needed to realize the full potential of AI," commented Sam Altman, co-founder and CEO of OpenAI, on the collaboration on Reuters. "AMD's leadership in high-performance chips will enable us to accelerate progress and bring the benefits of advanced AI to everyone faster."

    NetraMark – Strong cooperation

    NetraMark, an innovator in explainable artificial intelligence for the pharmaceutical and biotech industries, is offering a second buying opportunity after its initial upward momentum. After the stock rose by over 65% to EUR 1.11 between the end of April and August, it is currently undergoing consolidation. There is a striking support zone in the EUR 0.80 range, which has been successfully defended. The momentum is likely to receive a tailwind due to the positive indicator situation. Both the RSI and the MACD are on the verge of new buy signals.

    Looking at developments over the past few months, the Company, currently valued at around EUR 70 million, appears poised for its next quantum leap. With the launch of NetraAI 2.0, NetraMark is making a significant step toward precision medicine. The platform is already supporting a Phase III study by Asclepion Pharmaceuticals in the field of pediatric heart surgery, enabling the precise identification of subgroups of children who respond particularly well to the active ingredient L-citrulline.

    The Company is now venturing into an exceptionally complex field: glioblastoma research. In collaboration with the renowned US research center, the Mayo Clinic, NetraMark is developing an AI-powered analysis and decision-making tool to enable novel therapeutic approaches against one of the most aggressive brain tumors. To date, over 90% of all studies in this field have failed, partly due to imprecise patient selection and a lack of reliable biomarkers.

    Using so-called NetraPersonas, explainable patient subgroups are formed that provide detailed insights into disease progression and response to therapy. This is based on highly complex longitudinal data from cerebrospinal fluid, supplemented by state-of-the-art proteomics data from the SomaLogic platform. Among other things, tumor development in relapses, molecular effects of surgical interventions, and responses to chemotherapy and immunotherapy are analyzed.

    Adobe – Fundamentally cheap

    While investors are chasing the AI wave despite the sometimes exorbitant valuations, and stocks such as Nvidia and Palantir have multiplied their market value, Adobe is considered the disappointment in this sector par excellence. Since the beginning of the year, the stock of the developer of creative, design, and marketing applications, including well-known programs such as Photoshop, Illustrator, Premiere Pro, and Acrobat, has lost around 20% of its value and is currently trading at USD 347.25. Should the price fall below the current annual low of USD 332.01, this is likely to trigger a further sell-off towards the USD 275 mark, the low from 2022.

    However, the valuation argues against a further sell-off and higher price potential, especially after the recently published figures, which included a jump in both sales and earnings. Adobe shares are currently trading at a significant discount. At 17.5, the price-to-earnings ratio is not only around 25% below the industry average of 24.0, but also 45% below its own 5-year average. The same picture is reflected in the price-to-cash-flow ratio. The US company currently stands at 15.6, compared to 18.4 for the industry and 28.2 for the Company's historical average.

    At the same time, however, they also demonstrate Adobe's high cash conversion quality. Thanks to strong cash inflows, the Company can regularly carry out share buybacks worth billions. In the last quarter alone, 8 million shares totaling over USD 2.5 billion were repurchased, a clear sign of financial strength and confidence in the Company's own valuation.


    The AI wave continues to be ridden by investors. The former industry laggard, Adobe, is massively undervalued compared to its peer group. The partnership with OpenAI is giving AMD shares a boost, while NetraMark has successfully secured a far-reaching cooperation agreement.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 7th, 2025 | 07:45 CEST

    Aspermont, Palantir, RENK – AI sets the pace. Where is the next run?

    • Digitization
    • Technology
    • AI
    • Defense
    • Software
    • bigdata

    International stock markets are booming. The Dow Jones recently surpassed 47,000 points, seemingly unaffected by the US government shutdown. The topic of artificial intelligence (AI) continues to be the focus of investor interest, and recent company announcements are causing a stir. Japanese electronics giant Hitachi and ChatGPT provider OpenAI are partnering to build AI infrastructure and global data centers. Meanwhile, Fujitsu and leading AI chip manufacturer Nvidia are expanding their collaboration and plan to jointly develop a platform that uses AI in a targeted manner for specific industries, such as healthcare and robotics. In view of the AI boom, it is becoming increasingly compelling to explore second- and third-tier stocks that could benefit from the surge in innovation and investor interest.

    Read

    Commented by Armin Schulz on October 7th, 2025 | 07:20 CEST

    Cancer research with billion-dollar potential: How Bayer, Vidac Pharma, and BioNTech could come into play

    • Biotechnology
    • Biotech
    • Pharma
    • Innovations
    • Cancer

    The oncology market is booming like no other. Driven by technological quantum leaps and, unfortunately, rising case numbers, cancer treatment is becoming a highly lucrative innovation engine. The sector is growing at double-digit rates every year. Experts predict that the global market volume will break the USD 1 trillion mark within the next decade. No wonder, then, that the race for the next therapeutic breakthroughs in personalized medicines and AI-supported active ingredients is heating up. Investors are focusing not only on established players like Bayer, but also on up-and-coming specialists such as Vidac Pharma and mRNA pioneers like BioNTech.

    Read

    Commented by André Will-Laudien on October 7th, 2025 | 07:00 CEST

    Total boom! Not 10% returns per year, but per day! The portfolio rockets: Almonty, Plug Power, Nel ASA and AMD

    • Mining
    • Tungsten
    • Fuelcells
    • renewableenergies
    • AI
    • chips

    The financial markets are in a bullish mood. But not all stocks are performing like Almonty Industries, where the surge is driven purely by fundamental revaluation. After the gold rush in 2020/2021, hydrogen stocks underwent a prolonged 95% correction. For US industry leader Plug Power, this meant a sell-off from over USD 12 to a low of USD 0.75. In May, the correction came to an end, and the stock skyrocketed to over USD 4.75 yesterday – a fivefold increase in just four months. Nel ASA has followed a similar path, with a 15% turnaround from the bottom yesterday. These extreme movements are evidence of very high market liquidity. AMD surprised with a deal with OpenAI - fueling a 25% jump. The helium balloon keeps rising. Here is an overview of the action.

    Read